We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

220 hedge funds and large institutions have $2.55B invested in Agios Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 68 increasing their positions, 69 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

24% more capital invested

Capital invested by funds: $2.05B → $2.55B (+$494M)

23% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 35

3% more funds holding

Funds holding: 214 → 220 (+6)

2.77% more ownership

Funds ownership: 106.52% → 109.29% (+2.8%)

9% more call options, than puts

Call options by funds: $85.2M | Put options by funds: $78.2M

1% less repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 69

Holders
220
Holders Change
+6
Holders Change %
+2.8%
% of All Funds
2.89%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
43
Increased
68
Reduced
69
Closed
35
Calls
$85.2M
Puts
$78.2M
Net Calls
+$7.06M
Net Calls Change
+$4.49M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$77.1M
2
PBA
Paradigm Biocapital Advisors
New York
+$57.6M
3
TCM
TCG Crossover Management
California
+$27.6M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$18.6M
5
EAM
Erste Asset Management
Austria
+$16.5M

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$31.8M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$23.2M
3
Citadel Advisors
Citadel Advisors
Florida
-$22.2M
4
O
OrbiMed
New York
-$18.6M
5
Marshall Wace
Marshall Wace
United Kingdom
-$17.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
1
Farallon Capital Management
California
$232M +$512K +13,600 +0.2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$225M -$2.9M -77,143 -1%
BlackRock
3
BlackRock
New York
$182M -$10.8M -288,022 -6%
BG
4
Bellevue Group
Switzerland
$149M +$4.69M +124,586 +3%
EAM
5
Erste Asset Management
Austria
$109M +$16.5M +438,411 +19%
PBA
6
Paradigm Biocapital Advisors
New York
$107M +$57.6M +1,531,044 +134%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$99.2M +$77.1M +2,049,287 +485%
CC
8
Commodore Capital
New York
$93.9M +$500K +13,287 +0.6%
State Street
9
State Street
Massachusetts
$90.8M +$11.7M +311,599 +16%
Macquarie Group
10
Macquarie Group
Australia
$78.6M +$2.16M +57,505 +3%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$66.5M -$23.2M -617,311 -27%
TCM
12
TCG Crossover Management
California
$57.4M +$27.6M +733,038 +105%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$56.9M +$397K +10,560 +0.8%
FLSM
14
Frazier Life Sciences Management
California
$51.4M – – –
CP
15
Caligan Partners
New York
$45.4M +$2.25M +59,947 +6%
Bank of America
16
Bank of America
North Carolina
$45.4M +$365K +9,692 +0.9%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$41M -$3.19M -84,892 -8%
BNP Paribas Asset Management
18
BNP Paribas Asset Management
France
$39.6M -$1.11M -29,552 -3%
RSCM
19
Rock Springs Capital Management
Maryland
$38.5M -$1.17M -31,203 -3%
Deutsche Bank
20
Deutsche Bank
Germany
$37.2M +$194K +5,148 +0.6%
Fisher Asset Management
21
Fisher Asset Management
Washington
$34.9M -$278K -7,395 -0.8%
GKIM
22
GW&K Investment Management
Massachusetts
$34.2M -$590K -15,676 -2%
Goldman Sachs
23
Goldman Sachs
New York
$32.3M +$5.89M +156,705 +24%
Adage Capital Partners
24
Adage Capital Partners
Massachusetts
$32.1M +$339K +9,000 +1%
AC
25
Armistice Capital
New York
$30.7M -$15.2M -404,000 -35%
1
2 3 4 5

AGIO Hedge Fund Activity: Q3 2025 in Review

220 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2025, worth a combined $2.55B — up 24% from $2.05B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new AGIO positions and 35 closed out — a net gain of 8 holders — while 68 added to existing stakes and 69 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $77.1M. The largest seller was JP Morgan Chase, cutting an estimated $31.8M.

  • 220 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2025, up from 214 in Q2 2025.
  • Funds reported $2.55B of Agios Pharmaceuticals stock for Q3 2025, up 24% quarter-over-quarter.
  • 43 funds opened new Agios Pharmaceuticals positions in Q3 2025 and 35 closed out, a net change of +8 holders.
  • The largest Agios Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $77.1M added.
  • The largest Agios Pharmaceuticals seller in Q3 2025 was JP Morgan Chase, an estimated $31.8M sold.

Based on aggregated 13F filings for Q3 2025.